Product Images Envarsus XR

This is a prescription drug with the NDC code NDC68992-3075-1. The package insert should be referred to for dosage information. The drug should be stored at a temperature between 15°C and 30°C, and it is manufactured by Veloxis Pharmaceuticals. The medication guide must always be provided. The drug should be swallowed whole and not chewed or crushed. The description does not provide the name of the drug.*

This is dosage information for Envarsus XR, an extended-release tablet containing tacrolimus. The recommended temperature for storage is between 15°C-30°C (59°F - 86°F), and the medication should be swallowed whole, without chewing or crushing. The NDC number for this product is 68992-3075-3, and a medication guide should always be dispensed with it. This product is made by Veloxis Pharmaceuticals Inc.*

This is a pharmaceutical product package of Envarsus XR, containing tacrolimus extended-release tablets, used orally. Each once-daily tablet contains 0.75 mg of tacrolimus, and should be stored at controlled temperatures. The tablets should be swallowed whole, and not chewed, divided, or crushed. The tablets also contain inactive ingredients, such as hypromellose and lactose. Dosage information is available in the package inset, and a medication guide is also provided. This medication is produced by Veloxis Pharmaceuticals Inc.*

Envarsus XR is a tacrolimus tablet sold in a bottle with 30 tablets. Each extended-release tablet contains 0.75 mg tacrolimus. These tablets are designed to be swallowed whole and should not be chewed or crushed. The inactive ingredients of Envarsus XR include hypromellose, lactose monohydrate, polyethylene glycol, poloxamer, magnesium stearate, tartaric acid, butylated hydroxytoluene, and dimethicone. This medication should be stored at a controlled room temperature of around 25°C (77°F) with excursions permitted to 15°C~30°C (59°F~86°F). Veloxis Pharmaceuticals, Inc., manufactures Envarsus XR, and a medication guide should always accompany it. Dosage information is provided in the package insert. MeltDose technology is used to produce it.*

Envarsus XR is a medication with tacrolimus extended-release tablets in 1mg strength, taken once a day. It should be swallowed whole and not crushed or divided. The recommended dosage can be found in the package insert. The medication should be stored within the temperature range permitted, and always dispensed with a medication guide. Its manufacturer is Veloxis Pharmaceuticals, and contains 30 tablets per prescription.*

Envarsus XR is a medication available in the form of extended-release tablets and is used orally. The tablets come in a bottle of 100 and contain 1mg of tacrolimus each. The tablets must be swallowed whole and not chewed, divided, or crushed. The inactive ingredients include hypromellose, lactose monohydrate, polyethylene glycol, poloxamer, magnesium stearate, tartaric acid, butylated hydroxytoluene, and dimethicone. The medication guide technology used is MeltDose. Dosage information should be obtained from the package insert. Envarsus XR is produced by Veloxis Pharmaceuticals, Inc., and should be stored at 25°C (77°F), with excursions permitted to 15°C — 30°C (59°F-86°F). It is a prescription-only drug.*

Envarsus XR is a medication available in tablet form, containing tacrolimus as the active ingredient. It is an extended-release medication that is meant to be taken orally once per day as prescribed, with each tablet containing 1g of tacrolimus. The tablet should be swallowed whole without being chewed, divided, or crushed. The inactive ingredients include hypromellose lactose monohydrae, polyethylene glycol, poloxamer, magnesium stearate, tartaric acid, butylated hydroxytoluene, and dimeti. The dosage information can be found in the package insert, and the medication should only be used as prescribed.*

Envarsus XR is a medication that comes in the form of extended-release tablets containing tacrolimus. The medication is dispensed in a 100 tablet bottle, with a dosage strength of 4 mg. It is to be taken once daily, and must be kept at room temperature between 59°F - 86°F. The tablet should be swallowed whole and should not be chewed, divided or crushed. A medication guide must always be dispensed with the medication.*

This is a medication label for NDC 68992-3040-3, an extended-release tablet medication called Envarsus XR®. The dosage information is not available. It should be stored at 25°C (77°F) but can be permitted up to 15°C. It is a controlled substance and has a dosage of 4mg to be taken once daily. The tablet needs to be swallowed whole and should not be chewed, divided, or crushed. A medication guide must be dispensed with the medication. The label contains a lot number and expiration date.*

Envarsus XR is a medication containing tacrolimus extended-release tablets with each tablet containing 4mg tacrolimus. It includes inactive ingredients such as Hypromellose, lactose monohydrate, polyethylene glycol, poloxamer, magnesium stearate, tartric acid, butylated hydroxytoluene, and dimethicone, which are produced with the MeftDose Technology. The tablet is designed for oral use and should be swallowed whole without chewing, dividing or crushing. Dosage information can be found in the package insert and should always be dispensed with a medication guide. This medication should be stored at a temperature of 25°C (77°F), with excursions permitted to 15°C-30°C. It is manufactured for Veloxis Pharmaceuticals, Inc. and is only available with a prescription.*

Envarsus XR is a medication containing 4mg of tacrolimus. It comes in the form of an extended-release tablet that should be swallowed whole, and not chewed or crushed. Inactive ingredients include Hypromellose, lactose monohydrate, and magnesium stearate. The medication is produced using MeftDose® technology and should be stored at 25°C (77°F) with excursions permitted to 15°C ~ 30°C (6°F ~ 86°F). It is for oral use only and should be administered with a medication guide. Dosage information should be obtained from the package insert. The medication is manufactured for Veloxis Pharmaceuticals in Cary, North Carolina.*

This text provides information regarding the treatment of an individual using Envarsus XR and Tacrolimus capsule. It includes the average Tacrolimus trough concentrations at study visit for different days from randomization. The text also contains a legend describing the ranges and values of the trough concentrations. Overall, the text gives insight into the medication and monitoring of an individual's treatment.*